We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Red Blood Cell Folate Level Is a Biomarker for Risk of Neural Tube Defects

By LabMedica International staff writers
Posted on 13 Aug 2014
The importance of maintaining high red blood cell (RBC) levels of folate during pregnancy to reduce risk of neural tube defects was confirmed in a review of results obtained by a large study of expectant mothers in China.

A team of American and Chinese researchers worked with results obtained from 247,831 participants in a prospective community intervention project in China (1993–1995) that was designed to prevent neural tube defects with 400 micrograms/day folic acid supplementation. More...
An additional 1194 participants came from a population based randomized trial (2003–2005) designed to evaluate the effect of folic acid supplementation on blood folate concentration among Chinese women of reproductive age.

Results revealed that the risk of neural tube defects was high at the lowest estimated RBC folate concentrations (for example, 25.4 neural tube defects per 10,000 births at 500 nanomoles/L) and decreased as estimated RBC folate concentration increased. Risk of neural tube defects was substantially reduced at estimated RBC folate concentrations above 1,000 nanomoles/L (for example, six neural tube defects per 10,000 births at 1,180 nanomoles/L).

The data derived from the Chinese studies was consistent with the existing literature on the link between folate and neural tube defects. Furthermore, neural tube defect risk estimates developed using the proposed model and population level RBC information were consistent with the prevalence of neural tube defects in the American population before and after food fortification with folic acid. Therefore, the authors concluded that RBC folate concentrations, as a biomarker for risk of neural tube defects, could be used to facilitate evaluation of prevention programs as well as to identify subpopulations at elevated risk for a neural tube defect affected pregnancy due to folate insufficiency.

The study, which was carried out by investigators at the [US] Centers for Disease Control and Prevention (Atlanta, GA, USA) and Peking University, Beijing, China), was published in the July 29, 2014, online edition of the British Medical Journal.

Related Links:
Centers for Disease Control and Prevention
Peking University


Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Alcohol Testing Device
Dräger Alcotest 7000
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.